ArticleBrain and behavior2018
Discovery of restless legs syndrome plasmatic biomarkers by proteomic analysis.
Article in Brain and behavior, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Serum Concentrations of Cytokines in Patients With Restless Legs Syndrome.Journal of sleep research · 2026Article
- Serum Biomarkers in Restless Legs Syndrome: Beyond the Classical Iron Paradigm-A Scoping Review.International journal of molecular sciences · 2026Article
- Restless legs syndrome and periodic limb movements of sleep - the relationship with stroke and other cerebrovascular disease.Nature reviews. Neurology · 2026Review
- Assessing the association between multiple indicators of inflammation and sleep disorders in young and middle-aged women: insights from traditional and machine learning approaches.European journal of medical research · 2025Article
- Unveiling the pathophysiology of restless legs syndrome through transcriptome analysis.iScience · 2024Article
- Proteomic insights into the pathophysiology of periodic limb movements and restless legs syndrome.Sleep health · 2024Article
- Evaluation of the relationship between idiopathic restless legs syndrome and serum hepcidin levels.Brain and behavior · 2023Article
- Vitamin D and Restless Legs Syndrome: A Review of Current Literature.Tremor and other hyperkinetic movements (New York, N.Y.) · 2023Review
- Article
- A metabolic biomarker panel of restless legs syndrome in peritoneal dialysis patients.Metabolomics : Official journal of the Metabolomic Society · 2022Article
- Ischemic Stroke and Sleep: The Linking Genetic Factors.Cardiology and therapy · 2021Review
- Are Mannan-binding Lectine Serin Protease-2 and Alpha-1-microglobulin and Bukinin Precursor the Potential Biomarkers of Manic Episode? A Study via Urinary Proetomic Analysis.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2021Article
- Searching for Novel Candidate Biomarkers of RLS in Blood by Proteomic Analysis.Nature and science of sleep · 2021Article
- Restless legs syndrome is associated with mast cell activation syndrome.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2020Article
- Electric Stimulation of Neurogenesis Improves Behavioral Recovery After Focal Ischemia in Aged Rats.Frontiers in neuroscience · 2020Article
- Evaluation of potential cardiovascular risk protein biomarkers in high severity restless legs syndrome.Journal of neural transmission (Vienna, Austria : 1996) · 2019Article
- Discovery of restless legs syndrome plasmatic biomarkers by proteomic analysis.Brain and behavior · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRestless legs syndrome (RLS) can lead to severe clinical consequences, thus negatively impacts on patients' overall health and quality of life. Nevertheless, the pathophysiology of RLS is still unclear, resulting in underestimate, incorrect, or ignored diagnosis and in limited management and treatment. The aim of this study was to compare the plasma proteome of RLS patients and healthy controls, in the search of diagnostic biomarkers related to the disease severity. MATERIALS AND
methodsTwo-dimensional gel electrophoresis coupled with liquid chromatography-mass spectrometry was employed to analyze plasma samples of 34 patients with primary RLS, divided into two subgroups according to the disease severity: MMS group (mild-moderate symptoms) and HS group (severe and very severe symptoms), and 17 age- and sex-matched control subjects. Sleep quality, daytime sleepiness, and the level of depression were also evaluated.
resultsWe identified eight upregulated spots, corresponding to five unique proteins, in both RLS group vs. controls (alpha-1B-glycoprotein, alpha-1-acid glycoprotein 1, haptoglobin, complement C4-A, and immunoglobulin kappa constant); five increased spots, consistent with three unique proteins, only in HS-RLS (kininogen-1, immunoglobulin heavy constant alpha 1, and immunoglobulin lambda constant 2); one downregulated spot in both patient's groups (complement C3) and another one only in HS-RLS (alpha-1-antitrypsin).
conclusionsThe significantly different plasma proteins detected in RLS were mainly associated with inflammation, immune response, and cardiovascular disorders. Particularly, the gradual increasing in immunoglobulins could be indicative of the disease severity and evolution. Accordingly, these proteins may represent a valid set of useful biomarkers for RLS diagnosis, progression and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.